# A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

> **NCT06876662** · PHASE4 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 279 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT06876662
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2030-05
- **Final completion:** 2032-12
- **Target enrollment:** 279 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876662, "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06876662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*